Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia DOI Creative Commons

Hui-Sheng Zhou,

Yong-Feng Su,

Jun Wang

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 17, 2025

Introduction Anti-PD-1 monotherapy has shown limited clinical efficacy in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Our study aimed to analyze the effectiveness and safety of combining tislelizumab a hypomethylating agent (HMA) plus CAG regimen treating r/r AML, an increased sample size comparison, historical control group for more reliable data support (ClinicalTrials.gov identifier NCT04541277). Methods The included total 37 AML who received + HMA regimen. Results overall response rate was 69.4%, median survival 12.1 months event-free 6.2 months. Multivariate analysis revealed that aged 40 or above exhibited higher rate, while those lower burden (bone marrow blast percentage <40%) demonstrated improved survival. Additionally, bridging allogeneic hematopoietic stem cell transplantation associated extended Grade 2-3 immune-related adverse events were observed 8.5% patients, no deaths directly attributed these events. After propensity score matching, inclusion appeared positively influence compared controls treated Discussion Overall, combination rates maintaining low incidence severity patients. Clinical trial registration https://clinicaltrials.gov/ , NCT04541277.

Язык: Английский

Impact of Helicobacter pylori infection status on outcomes among patients with gastric cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis DOI
Francisco Cézar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Francinny Alves Kelly

и другие.

Microbial Pathogenesis, Год журнала: 2025, Номер unknown, С. 107407 - 107407

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia DOI Creative Commons

Hui-Sheng Zhou,

Yong-Feng Su,

Jun Wang

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 17, 2025

Introduction Anti-PD-1 monotherapy has shown limited clinical efficacy in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Our study aimed to analyze the effectiveness and safety of combining tislelizumab a hypomethylating agent (HMA) plus CAG regimen treating r/r AML, an increased sample size comparison, historical control group for more reliable data support (ClinicalTrials.gov identifier NCT04541277). Methods The included total 37 AML who received + HMA regimen. Results overall response rate was 69.4%, median survival 12.1 months event-free 6.2 months. Multivariate analysis revealed that aged 40 or above exhibited higher rate, while those lower burden (bone marrow blast percentage <40%) demonstrated improved survival. Additionally, bridging allogeneic hematopoietic stem cell transplantation associated extended Grade 2-3 immune-related adverse events were observed 8.5% patients, no deaths directly attributed these events. After propensity score matching, inclusion appeared positively influence compared controls treated Discussion Overall, combination rates maintaining low incidence severity patients. Clinical trial registration https://clinicaltrials.gov/ , NCT04541277.

Язык: Английский

Процитировано

0